Clearstead Advisors’s Editas Medicine EDIT Stock Holding History

Clearstead Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$399	Buy	123 +98	+392%	+$286	﹤0.01%	2993
2026 Q1	$62	Hold	25	–	–	﹤0.01%	2209
2025 Q4	$52	Hold	25	–	–	﹤0.01%	2600
2025 Q3	$87	Hold	25	–	–	﹤0.01%	2943
2025 Q2	$55	Hold	25	–	–	﹤0.01%	2665
2025 Q1	$29	Sell	25 -51	-67%	-$75	﹤0.01%	2174
2024 Q4	$97	Buy	76 +51	+204%	+$130	﹤0.01%	2049
2024 Q3	$86	Hold	25	–	–	﹤0.01%	2001
2024 Q2	$117	Hold	25	–	–	﹤0.01%	1983
2024 Q1	$143	Hold	25	–	–	﹤0.01%	1498
2023 Q4	$254	Hold	25	–	–	﹤0.01%	1483
2023 Q3	$195	Sell	25 -30	-55%	-$257	﹤0.01%	1443
2023 Q2	$453	Hold	55	–	–	﹤0.01%	1309
2023 Q1	$399	Hold	55	–	–	﹤0.01%	1317
2022 Q4	$488	Hold	55	–	–	﹤0.01%	1234
2022 Q3	$1K	Hold	55	–	–	﹤0.01%	1140
2022 Q2	$1K	Hold	55	–	–	﹤0.01%	1170
2022 Q1	$1K	Hold	55	–	–	﹤0.01%	1277
2021 Q4	$1K	Hold	55	–	–	﹤0.01%	1170
2021 Q3	$2K	Buy	55 +10	+22%	+$548	﹤0.01%	1120
2021 Q2	$3K	Buy	45 +20	+80%	+$739	﹤0.01%	961
2021 Q1	$1K	Buy	+25	New	+$1.42K	﹤0.01%	1020

Other funds holding EDIT

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Clearstead Advisors's EDIT Position: Q2 2026 in Review

Clearstead Advisors increased its Editas Medicine (EDIT) stake by 392% in Q2 2026, buying an estimated $286 and bringing the position to 123 shares worth $399. The position accounts for ﹤0.01% of the portfolio, ranked #2993.

Clearstead Advisors first reported a position in EDIT in Q1 2021 and has held it in 22 quarters since. The position peaked at $3K in Q2 2021. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

Clearstead Advisors held 123 shares of Editas Medicine worth $399 as of Q2 2026.
Clearstead Advisors bought 98 Editas Medicine shares in Q2 2026, an estimated $286.
Editas Medicine made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2993 holding.
Clearstead Advisors first reported a position in Editas Medicine in Q1 2021 and has held it in 22 quarters since.
Clearstead Advisors's Editas Medicine position peaked at $3K in Q2 2021.
214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.